In November 2019, a class-action lawsuit was filed against AMAG, Inc. for allegedly falsely marketing Makena as a medication that “lower[s] the risk of having another preterm baby in women who are pregnant with one baby, and who’ve unexpectedly delivered one baby too early (before 37 weeks) in the past” when, according to plaintiffs, scientific evidence does not support such claims. (Faughnan et al v. AMAG, Inc., Case No. 19-cv-1394, N. D. NY.)

Print Friendly, PDF & Email

Tags: ,

Leave a Reply

Back to Top ↑
  • Search Class-Action Tracker

  • Recent Class Actions

  • The Class-Action Tracker is intended to notify consumers about false advertising class-action lawsuits filed around the country, but does not necessarily reflect’s opinion with respect to the lawsuits or disposition of the cases

  • Sign Up for E-mail Updates